Wie in der Analyse schon beschrieben. Telix rekrutiert nun auch bei Blasenkrebs. Heute die Meldung von Telix. Am Ende des Tages ist das nun in einem Bereich, dass für Telix und Heidelberg Pharma Umsätze im Milliardenbereich addressiert. Tolle Entwicklung. Und dies kostet HPHA keinen Cent mehr. Die Kosten übernimmt alleine Telix.
First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
Melbourne (Australia) – 23 June 2021. Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the
‘Company’) today announces that a first patient has been dosed in a Phase I study of TLX250-CDx
(
89Zr-DFO-girentuximab) in patients with urothelial carcinoma or bladder cancer at Fiona Stanley
Hospital in Perth, Western Australia.
The objective of the ZiP-UP (Zirconium-girentuximab PET in Urothelial Cancer Patients) study is to
evaluate the feasibility of using TLX250-CDx PET/CT1 in the detection of localised and metastatic
urothelial carcinoma or bladder cancer. Carbonic anhydrase IX (CA9) is a target that is overexpressed in many solid tumours, including urologic malignancies. ZiP-UP is an investigator-led
study conducted by Professor Dickon Hayne at the Fiona Stanley Hospital in Perth, Australia with
the goal of evaluating how CA9 imaging can be utilised for cancer diagnosis and staging, and to
develop a deeper understanding of the utility of CA9 as a therapeutic target in this patient population.
The trial will recruit 20 patients over 12 months: ten patients with known metastatic urothelial
carcinoma or bladder cancer; and ten patients that require primary staging of localised urothelial
carcinoma or bladder cancer.
ZiP-UP is the first in a series of studies that will harness TLX250-CDx to evaluate CA9 expression
in cancers other than renal cancer, currently the focus of the ZIRCON (imaging) and STARLITE
(therapy) studies. Other collaborative studies are in development for ovarian, triple negative breast,
colorectal, head and neck, lung, and pancreatic cancers.
Principal Investigator for the ZiP-UP study, Professor Dickon Hayne stated, “In a cancer where
outcomes are worsening throughout Australia, better staging and therapy planning are absolutely
essential. We are therefore pleased to have dosed a first patient in this important diagnostic study,
which has potential to extend into therapy via the ‘theranostic’ companion investigational asset,
TLX250 (177Lu-DOTA-girentuximab).”
Telix CEO, Dr Christian Behrenbruch added, “We are pleased that a first patient has been dosed in
this study exploring the clinical utility of TLX250-CDx to image other cancers, beyond renal cancer,
and in indications where conventional imaging has limitations. This candidate has been granted
Breakthrough Therapy designation by the US FDA for renal cancer imaging and therefore it is
meaningful to test the potential of CA9 targeting in other cancers with the goal of rapid indication
expansion beyond the initial kidney cancer application. We wish to express our gratitude to Professor
Dickon Hayne and his clinical team, as well as the patients that will contribute to the study.”
Zurück
Weiter
Werbung
